182 related articles for article (PubMed ID: 22918769)
1. High uptake of (68)Ga-DOTATOC in spleen as compared to splenosis: measurement by PET/CT.
Kulkarni HR; Prasad V; Kaemmerer D; Hommann M; Baum RP
Recent Results Cancer Res; 2013; 194():373-8. PubMed ID: 22918769
[TBL] [Abstract][Full Text] [Related]
2. Differential uptake of (68)Ga-DOTATOC and (68)Ga-DOTATATE in PET/CT of gastroenteropancreatic neuroendocrine tumors.
Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C
Recent Results Cancer Res; 2013; 194():353-71. PubMed ID: 22918768
[TBL] [Abstract][Full Text] [Related]
3. Prospective Within-Patient Assessment of the Impact of an Unlabeled Octreotide Pre-dose on the Biodistribution and Tumor Uptake of
Lodge MA; Solnes LB; Chaudhry MA; Wahl RL
Mol Imaging Biol; 2021 Oct; 23(5):766-774. PubMed ID: 33829361
[TBL] [Abstract][Full Text] [Related]
4. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification.
Velikyan I; Sundin A; Sörensen J; Lubberink M; Sandström M; Garske-Román U; Lundqvist H; Granberg D; Eriksson B
J Nucl Med; 2014 Feb; 55(2):204-10. PubMed ID: 24379222
[TBL] [Abstract][Full Text] [Related]
5. Additional information gained by positron emission tomography with (68)Ga-DOTATOC for suspected unknown primary or recurrent neuroendocrine tumors.
Nakamoto Y; Sano K; Ishimori T; Ueda M; Temma T; Saji H; Togashi K
Ann Nucl Med; 2015 Jul; 29(6):512-8. PubMed ID: 25894056
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous 68Ga-DOTATOC PET/MRI in patients with gastroenteropancreatic neuroendocrine tumors: initial results.
Beiderwellen KJ; Poeppel TD; Hartung-Knemeyer V; Buchbender C; Kuehl H; Bockisch A; Lauenstein TC
Invest Radiol; 2013 May; 48(5):273-9. PubMed ID: 23493121
[TBL] [Abstract][Full Text] [Related]
7. Usefulness of combined imaging with
Maffey-Steffan J; Uprimny C; Moncayo R; Kroiss AS; Virgolini IJ
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(5):325-327. PubMed ID: 29739708
[No Abstract] [Full Text] [Related]
8. Comparison between F-18 fluorodeoxyglucose and Ga-68 DOTATOC in metastasized melanoma.
Brogsitter C; Zöphel K; Wunderlich G; Kämmerer E; Stein A; Kotzerke J
Nucl Med Commun; 2013 Jan; 34(1):47-9. PubMed ID: 23111377
[TBL] [Abstract][Full Text] [Related]
9. Role of (68)Ga-DOTATOC PET/CT in the evaluation of primary pulmonary carcinoids.
Jindal T; Kumar A; Venkitaraman B; Dutta R; Kumar R
Korean J Intern Med; 2010 Dec; 25(4):386-91. PubMed ID: 21179276
[TBL] [Abstract][Full Text] [Related]
10. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data.
Hofmann M; Maecke H; Börner R; Weckesser E; Schöffski P; Oei L; Schumacher J; Henze M; Heppeler A; Meyer J; Knapp H
Eur J Nucl Med; 2001 Dec; 28(12):1751-7. PubMed ID: 11734911
[TBL] [Abstract][Full Text] [Related]
11. ⁶⁸Ga-DOTA⁰-Tyr³-octreotide positron emission tomography in head and neck squamous cell carcinoma.
Schartinger VH; Dudás J; Decristoforo C; Url C; Schnabl J; Göbel G; Virgolini IJ; Riechelmann H; Rasse M; Waitz D; Putzer D
Eur J Nucl Med Mol Imaging; 2013 Sep; 40(9):1365-72. PubMed ID: 23685751
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of
Sawicki LM; Deuschl C; Beiderwellen K; Ruhlmann V; Poeppel TD; Heusch P; Lahner H; Führer D; Bockisch A; Herrmann K; Forsting M; Antoch G; Umutlu L
Eur Radiol; 2017 Oct; 27(10):4091-4099. PubMed ID: 28439648
[TBL] [Abstract][Full Text] [Related]
13. 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors.
Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C
J Nucl Med; 2011 Dec; 52(12):1864-70. PubMed ID: 22072704
[TBL] [Abstract][Full Text] [Related]
14. Visualization of somatostatin receptors in prostate cancer and its bone metastases with Ga-68-DOTATOC PET/CT.
Luboldt W; Zöphel K; Wunderlich G; Abramyuk A; Luboldt HJ; Kotzerke J
Mol Imaging Biol; 2010; 12(1):78-84. PubMed ID: 19421819
[TBL] [Abstract][Full Text] [Related]
15. Focal uptake of 68Ga-DOTATOC in the pancreas: pathological or physiological correlate in patients with neuroendocrine tumours?
Al-Ibraheem A; Bundschuh RA; Notni J; Buck A; Winter A; Wester HJ; Schwaiger M; Scheidhauer K
Eur J Nucl Med Mol Imaging; 2011 Nov; 38(11):2005-13. PubMed ID: 21792572
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of atypical
Gossili F; Almasi CE; Zacho HD
Hell J Nucl Med; 2023; 26(2):94-98. PubMed ID: 37527044
[TBL] [Abstract][Full Text] [Related]
17. The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors.
Frilling A; Sotiropoulos GC; Radtke A; Malago M; Bockisch A; Kuehl H; Li J; Broelsch CE
Ann Surg; 2010 Nov; 252(5):850-6. PubMed ID: 21037441
[TBL] [Abstract][Full Text] [Related]
18. Comparison of 68Ga-DOTATOC biodistribution in patients with and without spleenectomy.
Kratochwil C; Mavriopoulou E; Rath D; Afshar-Oromieh A; Apostolopoulos D; Haufe S; Mier W; Haberkorn U; Giesel FL
Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):116-20. PubMed ID: 24382404
[TBL] [Abstract][Full Text] [Related]
19. Lower
Tjörnstrand A; Casar-Borota O; Heurling K; Schöll M; Gjertsson P; Himmelman J; Itsenko O; Ragnarsson O; Filipsson Nyström H
Clin Endocrinol (Oxf); 2020 Mar; 92(3):222-231. PubMed ID: 31868239
[TBL] [Abstract][Full Text] [Related]
20. Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy.
Putzer D; Gabriel M; Henninger B; Kendler D; Uprimny C; Dobrozemsky G; Decristoforo C; Bale RJ; Jaschke W; Virgolini IJ
J Nucl Med; 2009 Aug; 50(8):1214-21. PubMed ID: 19617343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
